|
These studies have recently activated.
More information can be found on CTSU.
• NRG-BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
• S2200: A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
• NRG-CC010: A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer
| |
|
-
Wake Forest Annual Meeting: October 10-12, 2022 – Myrtle Beach, SC
-
Register Here
-
SWOG Fall Meeting: October 19-22, 2022 – Chicago, IL
-
Register Here
-
ECOG-ACRIN Fall Meeting: October 26-28, 2022 – Washington, DC
-
Register Here
-
Alliance Fall Meeting: November 2-5, 2022 – Chicago, IL
-
Register Here
| |
Accruals & Biospecimens-Special Entries | |
Under-Represented Populations | | |
|
Shoutout to the Cancer Control & CCDR Team at SMC for 25 enrollments in August!! | |
|
Prostate Cancer Awareness Month
September is National Prostate Cancer Awareness Month! Prostate Cancer Awareness Month aims to increase public awareness of the importance of prostate health and screenings, educate about risk factors and symptoms and advocate for further research on prostate health issues.
According to the S.C Department of Health and Environmental Control (DHEC), prostate cancer is the most diagnosed cancer and the second most common cause of death among men in South Carolina. According to the American Cancer Society, several risk factors are associated with prostate cancer, including family history, race, diet, and, most commonly, age. Specifically, men older than 65 are at a higher risk for prostate cancer, and Black men have an 80 percent higher rate of prostate cancer than any other race in the United States.
Prostate Cancer Awareness Month promotes early prevention and intervention. Therefore, prostate cancer screenings are offered nationwide for men who qualify, along with education on reducing prostate cancer risk.
Upstate Carolina NCORP would like to highlight three research studies that we participate in that focus on prostate cancer!
| |
|
NRG-GU009:
Parallel Phase III Randomized Trials for High-Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
*Prostate RNA Expression/Decipher to Individualize Concurrent Therapy with Radiation*
-
Primary Objective:
- De-Intensification Study: To determine whether men with NCCN high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (≤0.85) can be treated with 12 months of ADT plus RT instead of 24 months ADT+RT and experience non-inferior metastasis-free survival.
- Intensification Study: To determine whether men with NCCN high risk prostate cancer who are in the upper 1/3 of Decipher genomic risk (>0.85) or have node-positive disease by conventional imaging (MRI or CT scan) will have a superior metastasis-free survival through treatment intensification with apalutamide added to the standard of RT plus 24-month ADT.
Wake Forest 1802:
Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
- Primary Objective
- Compare changes in work ability reported by African American and white prostate cancer survivors, before treatment and 6 months after treatment completion.
NCI 10323:
Cancer Moonshot Biobank Research Protocol
- Primary Objective
- To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCORP sites.
Site Recognition: Bon Secours St. Francis is the top accruing site for the NRG-GU009 study, and Spartanburg is the top accruing site for the WF-1802 PCW study! Way to go UC-NCORP
| |
Do you have any staff you would like highlighted in The Connector?
Please submit it by the 15th of the month to Alaina: akennedy@srhs.com
| |
Connect with us on LinkedIn!
| |
|
|
Administrator
Kamara Mertz-Rivera, MA, CCRC
Email: UpstateNCORP@srhs.com
Phone: 864-560-6104
eRegulatory Systems
Laura Bailey, BS, CCRP
Email: UpstateNCORPRegulatory@srhs.com
Phone: 864-560-6954
Regulatory
Josh Acuna, MPH
Email: UpstateNCORPRegulatory@srhs.com
Phone: 864-560-1049
AYA Coordinator
Heather Schwartz, MPH, HTL
Email: heather_schwartz@bshsi.org
Phone: 864-603-6212
| |
|
Grant Manager
Alex Akkary, MBA
Email: UpstateNCORPFinance@srhs.com
Phone: 864-560-6967
Quality Assurance
Kristen Ford, BSN MSN
Email: UpstateNCORPQA@srhs.com
Phone: 864-530-6554
CCDR Lead
Melyssa Foust, MSN, RN, OCN
Email: UpstateNCORPCCDR@srhs.com
Phone: 864-560-1035
Community & Social Media
Alaina Kennedy, BA
Email: akennedy@srhs.com
Phone: 864-560-6882
| |
2759 Hwy 14 South • Greer • SC • 29651 | | | | | |
